Literature DB >> 32313480

Clinical and histological response to combination nivolumab and ipilimumab in metastatic renal cell carcinoma.

Yadav Pandey1, Aasiya Matin2, Brannon Broadfoot3, Anuradha Kunthur2.   

Abstract

Patients with renal cell carcinoma (RCC) often remain asymptomatic until the disease is advanced, with about 25% presenting at an advanced stage. We present a case of metastatic RCC treated with combination ipilimumab and nivolumab with complete radiological and pathological response. Currently, combination nivolumab and ipilimumab is a preferred option for intermediate- and poor-risk patients with clear cell stage IV RCC.
Copyright © 2020 Baylor University Medical Center.

Entities:  

Keywords:  Complete response; immunotherapy; nivolumab and ipilimumab; renal cell carcinoma

Year:  2020        PMID： 32313480      PMCID： PMC7155964          DOI： 10.1080/08998280.2020.1717264

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


  14 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

2.  Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.

Authors:  Aaron M Goodman; Shumei Kato; Lyudmila Bazhenova; Sandip P Patel; Garrett M Frampton; Vincent Miller; Philip J Stephens; Gregory A Daniels; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2017-08-23       Impact factor: 6.261

3.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.

Authors:  Brian I Rini; Elizabeth R Plimack; Viktor Stus; Rustem Gafanov; Robert Hawkins; Dmitry Nosov; Frédéric Pouliot; Boris Alekseev; Denis Soulières; Bohuslav Melichar; Ihor Vynnychenko; Anna Kryzhanivska; Igor Bondarenko; Sergio J Azevedo; Delphine Borchiellini; Cezary Szczylik; Maurice Markus; Raymond S McDermott; Jens Bedke; Sophie Tartas; Yen-Hwa Chang; Satoshi Tamada; Qiong Shou; Rodolfo F Perini; Mei Chen; Michael B Atkins; Thomas Powles
Journal:  N Engl J Med       Date:  2019-02-16       Impact factor: 91.245

4.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

Review 5.  Check point inhibitors a new era in renal cell carcinoma treatment.

Authors:  Mohamed Alsharedi; Heather Katz
Journal:  Med Oncol       Date:  2018-05-04       Impact factor: 3.064

6.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma
Journal:  N Engl J Med       Date:  2015-09-25       Impact factor: 91.245

7.  Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Authors:  Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

8.  Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line.

Authors:  J H Finke; P Rayman; M Edinger; R R Tubbs; J Stanley; E Klein; R Bukowski
Journal:  J Immunother (1991)       Date:  1992-01

9.  Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.

Authors:  Cora N Sternberg; Ian D Davis; Jozef Mardiak; Cezary Szczylik; Eunsik Lee; John Wagstaff; Carlos H Barrios; Pamela Salman; Oleg A Gladkov; Alexander Kavina; Juan J Zarbá; Mei Chen; Lauren McCann; Lini Pandite; Debasish F Roychowdhury; Robert E Hawkins
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

Review 10.  Defining the role of the tumor vasculature in antitumor immunity and immunotherapy.

Authors:  Marco B Schaaf; Abhishek D Garg; Patrizia Agostinis
Journal:  Cell Death Dis       Date:  2018-01-25       Impact factor: 8.469
View more
  1 in total

1.  A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma.

Authors:  Hana Studentova; Anezka Zemankova; Martina Spisarova; Daniela Skanderova; Zbynek Tudos; Bohuslav Melichar; Vladimir Student
Journal:  Medicina (Kaunas)       Date:  2022-02-23       Impact factor: 2.430
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.